Can we use statins to prevent stroke in Fabry disease?

Area of Science:

• Biochemistry
• Genetics
• Neurology

Background:

• Fabry disease is a rare X-linked lysosomal storage disorder.
• Deficiency of alpha-galactosidase A leads to glycolipid accumulation.
• Cerebrovascular complications, including deep-white matter lesions, are a major cause of mortality.

Purpose of the Study:

• To evaluate the evidence for statin use in Fabry disease vasculopathy.
• To explore the potential beneficial effects of statins in managing Fabry disease complications.

Main Methods:

• Review of recent clinical trials and scientific literature.
• Analysis of proposed mechanisms for statin-induced neuroprotection and pleiotropic effects.

Main Results:

• Statins have demonstrated neuroprotective properties in other conditions.
• Pleiotropic effects of statins may contribute to vascular protection.
• Evidence suggests potential benefits in mitigating cerebrovascular events.

Conclusions:

• Statins show promise in addressing vasculopathy in Fabry disease.
• Further clinical evaluation is warranted to establish efficacy and safety.
• Statins could be a valuable therapeutic option for Fabry disease patients at risk of stroke.